Immunotherapy is regarded as the most promising treatment for cancers. Various cancer
immunotherapies, including adoptive cellular immunotherapy, tumor vaccines, antibodies …

The management of advanced-stage renal cell carcinoma (RCC) has been transformed by
the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not …

Regulatory T (Treg) cells, an immunosuppressive subset of CD4+ T cells characterized by
the expression of the master transcription factor forkhead box protein P3 (FOXP3), are a …

Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in
cancer treatment that use checkpoint inhibitors,. For treatments using checkpoint inhibitors to …

Immunotherapy has revolutionized cancer treatment over the past decade. Nonetheless,
prolonged survival is limited to relatively few patients. Cancers enforce a multifaceted …

Depleting regulatory T cells (Treg cells) to counteract immunosuppressive features of the
tumor microenvironment (TME) is an attractive strategy for cancer treatment; however …

Cancer vaccines, which are designed to amplify tumour-specific T cell responses through
active immunization, have long been envisioned as a key tool of effective cancer …

The successful outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating
hematologic cancers have increased the previously unprecedented excitement to use this …

Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned
from a nonspecific immune approach (in the cytokine era), to targeted therapy against …

Adoptive T cell therapy (ACT) refers to the therapeutic use of T cells. T cells genetically
engineered to express chimeric antigen receptors (CAR) constitute the most clinically …